MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- ABBOTT INDIA - ACTAVIS (US)
ABBOTT INDIA vs ACTAVIS (US) - Comparison Results
ABBOTT INDIA Change
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 ABBOTT INDIA  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ABBOTT INDIA Mar-19 |
ACTAVIS Dec-18 |
ABBOTT INDIA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 8,834 | 14,011 | - | |
| Low | Rs | 5,458 | 9,399 | - | |
| Sales per share (Unadj.) | Rs | 1,731.1 | 3,437.0 | - | |
| Earnings per share (Unadj.) | Rs | 211.9 | -1,107.1 | - | |
| Cash flow per share (Unadj.) | Rs | 219.9 | 362.2 | - | |
| Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.9 | 0 | - | |
| Book value per share (Unadj.) | Rs | 945.2 | 14,175.9 | - | |
| Shares outstanding (eoy) | m | 21.25 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.1 | 3.4 | 121.2% | |
| Avg P/E ratio | x | 33.7 | -10.6 | -318.9% | |
| P/CF ratio (eoy) | x | 32.5 | 32.3 | 100.6% | |
| Price / Book Value ratio | x | 7.6 | 0.8 | 915.6% | |
| Dividend payout | % | 30.7 | 0 | - | |
| Avg Mkt Cap | Rs m | 151,848 | 3,893,108 | 3.9% | |
| No. of employees | `000 | 3.5 | 16.9 | 20.6% | |
| Total wages/salary | Rs m | 4,356 | 0 | - | |
| Avg. sales/employee | Rs Th | 10,555.5 | 67,641.2 | 15.6% | |
| Avg. wages/employee | Rs Th | 1,249.9 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,292.2 | -21,787.3 | -5.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 36,786 | 1,143,137 | 3.2% | |
| Other income | Rs m | 1,133 | 21,861 | 5.2% | |
| Total revenues | Rs m | 37,919 | 1,164,997 | 3.3% | |
| Gross profit | Rs m | 6,047 | 29,956 | 20.2% | |
| Depreciation | Rs m | 169 | 488,666 | 0.0% | |
| Interest | Rs m | 23 | 65,966 | 0.0% | |
| Profit before tax | Rs m | 6,989 | -502,815 | -1.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 128,238 | 0.0% | |
| Tax | Rs m | 2,485 | -6,372 | -39.0% | |
| Profit after tax | Rs m | 4,503 | -368,205 | -1.2% | |
| Gross profit margin | % | 16.4 | 2.6 | 627.3% | |
| Effective tax rate | % | 35.6 | 1.3 | 2,806.1% | |
| Net profit margin | % | 12.2 | -32.2 | -38.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 27,610 | 468,855 | 5.9% | |
| Current liabilities | Rs m | 8,569 | 414,764 | 2.1% | |
| Net working cap to sales | % | 51.8 | 4.7 | 1,093.9% | |
| Current ratio | x | 3.2 | 1.1 | 285.0% | |
| Inventory Days | Days | 60 | 20 | 307.4% | |
| Debtors Days | Days | 27 | 66 | 41.3% | |
| Net fixed assets | Rs m | 1,057 | 129,397 | 0.8% | |
| Share capital | Rs m | 213 | 0 | - | |
| Net worth | Rs m | 20,086 | 4,714,905 | 0.4% | |
| Long term debt | Rs m | 0 | 1,660,289 | 0.0% | |
| Total assets | Rs m | 29,409 | 7,370,469 | 0.4% | |
| Interest coverage | x | 311.6 | -6.6 | -4,705.2% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 1.3 | 0.2 | 806.5% | |
| Return on assets | % | 15.4 | -4.1 | -375.3% | |
| Return on equity | % | 22.4 | -7.8 | -287.1% | |
| Return on capital | % | 34.9 | -4.8 | -721.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,991 | 408,400 | 1.2% | |
| From Investments | Rs m | -2,570 | 224,362 | -1.1% | |
| From Financial Activity | Rs m | -1,428 | -700,936 | 0.2% | |
| Net Cashflow | Rs m | 993 | -67,834 | -1.5% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.41 Rs / USD
Compare ABBOTT INDIA With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: NOVARTIS WYETH STERLING BIOTECH ALKEM LABORATORIES DIVIS LABORATORIES
Today's Market
Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
Related Views On News
ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)
Aug 18, 2020 | Updated on Aug 18, 2020For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Penny Stock Master Series: The Quest for 10X Profits in 10 Years (Profit Hunter)
Feb 12, 2021This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
More
